Graves’ disease with spontaneous resolution following ocrelizumab in primary progressive multiple sclerosis
Objectives. Immune reconstitution therapies (IRT), which include antibody-based cell-depleting therapies targeting CD52+ (alemtuzumab) or CD20+ (rituximab, ocrelizumab) leukocytes, are approved for the treatment of multiple sclerosis. Thyroid autoimmunity is a common adverse effect of alemtuzumab tr...
Saved in:
Main Authors: | Duarte Diana Borges, Silva Ana Martins da, Freitas Claudia, Cardoso Helena |
---|---|
Format: | article |
Language: | EN |
Published: |
Sciendo
2021
|
Subjects: | |
Online Access: | https://doaj.org/article/7f501c0e5c6b45d6a40e08bd41592731 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
LDL and HDL lipoprotein subfractions in multiple sclerosis patients with decreased insulin sensitivity
by: Radikova Zofia, et al.
Published: (2018) -
A case of hypercalcaemic crisis secondary to coexistence of primary hyperparathyroidism and Graves’ disease
by: Baldane S, et al.
Published: (2016) -
The effect of radioiodine treatment on the characteristics of TRAb in Graves’ disease
by: Ya Fang, et al.
Published: (2021) -
Unilateral gynecomastia as an initial presentation of hyperthyroid Graves’ disease
by: Titipatima Sakulterdkiat, et al.
Published: (2021) -
New horizons for multiple sclerosis therapeutics: milestones in the development of ocrelizumab
by: Frau J, et al.
Published: (2018)